Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.68 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.68 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.68 |
| ▸ | SRM | P19623 | 3/20 | 0.66 |
| ▸ | SMS | P52788 | 1/20 | 0.66 |
| ▸ | PNMT | P11086 | 1/20 | 0.65 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.65 |
| ▸ | AHCY | P23526 | 6/20 | 0.64 |
| ▸ | NADK | O95544 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770054 | 0.93 | SRM (0.69) | DOT1LDNMT3BPRMT7SRMSMS | |
| SCHEMBL11139574 | 0.84 | EHMT1 (0.71) | DOT1LDNMT3BPRMT7PNMTDNMT1 | |
| Methylthioadenosine SCHEMBL7124285 | 0.83 | DOT1L (0.78) | DOT1LDNMT3BPRMT7SRMSMS | |
| SCHEMBL11135998 | 0.81 | DOT1L (0.66) | DOT1LDNMT3BPRMT7SRMSMS | |
| SCHEMBL1398379 | 0.81 | DOT1L (1.00) | DOT1LDNMT3BPRMT7SRMPNMT | |
| SCHEMBL14174636 | 0.81 | DOT1L (1.00) | DOT1LDNMT3BPRMT7SRMPNMT | |
| SCHEMBL14158851 | 0.81 | DOT1L (1.00) | DOT1LDNMT3BPRMT7SRMPNMT | |
| SCHEMBL10665713 | 0.81 | DOT1L (1.00) | DOT1LDNMT3BPRMT7SRMPNMT | |
| SCHEMBL19433787 | 0.80 | DOT1L (0.73) | DOT1LDNMT3BPRMT7SRMSMS | |
| SCHEMBL30249742 | 0.79 | SRM (1.00) | DOT1LDNMT3BPRMT7SRMSMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC | 2018-12-20 | — | — | US | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2018204764-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION (US) | 2018-11-08 | — | — | WO | disclosed |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-20050176828-A1 | Hydrophobic polyamine analogs and methods for their use | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005023310-A2 | POLYAMINE-METAL CHELATOR CONJUGATES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20040229886-A1 | Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation | QUARK BIOTECH, INC. & SHIONOGI CO., LTD. | 2004-11-18 | — | — | US | disclosed |
| US-6696454-B2 | ADMINISTERING AN INHIBITOR OF SPERMIDINE BIOSYNTHESIS; PREFERRED ARE DCHA (DICYCLOHEXYLAMINE), ADODATO, AND TRANS-4-METHYLCYCLOHEXYLAMINE (4MCHA) | QUARK BIOTECH, INC. | 2004-02-24 | — | — | US | disclosed |
| EP-1373185-A2 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | Mediquest Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | AMINEX THERAPEUTICS, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030118539-A1 | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-06-26 | — | — | US | disclosed |
| US-20020160978-A1 | Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation | QUARK PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | disclosed |
| WO-2002053519-A2 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | MEDIQUEST THERAPEUTICS, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| US-4376116-A | TREATMENT OF CYSTIC FIBROSIS AND PARASITIC INFECTIONS | RESEARCH CORPORATION (US) | 1983-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | SRM, SMS, HNMT | DOT1L 595/4885DNMT3B 1116/4885PRMT7 31/4885 |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | SRM, PMP22, SMS | DOT1L 2184/4885DNMT3B 563/4885PRMT7 182/4885 |
| US-20050176828-A1 | Hydrophobic polyamine analogs and methods for their use | SRM, SMS, HNMT | DOT1L 595/4885DNMT3B 1116/4885PRMT7 31/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | DOT1L 4266/4885DNMT3B 520/4885PRMT7 1812/4885 |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PMP22, MAG, GMFG | DOT1L 4058/4885DNMT3B 118/4885PRMT7 642/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | DOT1L 4058/4885DNMT3B 118/4885PRMT7 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.